|
Avanti
Therapeutics-genome concepts (AT-GC) is a developer of novel
gene based immunotherapeutics with a commitment to treating and
preventing, cancer, infectious diseases and multi drug resistant
infections by understanding and directing the immune system.
AT-GC is focused on immunotherapeutic products and has a broad
technology platform enabling both fully integrated vaccine
design and the use of its separate, proprietary product
components on a standalone basis. AT-GC currently has multiple
programs in Research & Development that will be ready in next
four quarters for clinical development.
The company
partners with numerous developers and marketers of
biopharmaceuticals, targeting products that are Powered by
Doctor DNA™
technology
with the goal of making its potential products available to
patients around the world. AT-GC was founded in 2002 and is
headquartered in Clarksburg, Maryland, with additional
operations in Burlington, MA, and Gujarat, India.
To learn more about investigational drugs Avanti Therapeutics is
developing, visit the
Pipeline section.
Avanti Therapeutics has recently diversified into Quality by Design
manufacturing for
the biopharmaceutical industry. See our
AT-GC BioPharm's
website for
further information.
We have recently started a nanotechnology based process analytics division for
rapid analytical platform for biopharmaceutical industry. See our
AT-GC analytics
website for further information.
Avanti Therapeutics and its two divisions (AT-GC BioPharm and AT-GC Analytics)
are privately owned. For investment interest in any of our divisions please
contact our CEO or Investor Relations Department
investor.relations@at-gc.com
|
